Информация на сайте доступна только для специалистов здравоохранения.

Пожалуйста, подтвердите, что Вы являетесь специалистом здравоохранения.

ВНИМАНИЕ! Компания снимает с себя ответственность за предоставление информации о рецептурном препарате в случае, если при подтверждении статуса специалиста сферы здравоохранения, лицо таковым не является.

Да, являюсь специалистом в области здравоохранения

Церебролизин, ЭВЕР

Ebewe's neuro news

Категория: Инсульт

Around the world, intensive work is underway to develop new drugs for fighting degenerative brain disorders, and particularly Alzheimer’s dementia

The greatest expectations focus on measures for improving neurotransmission and inhibiting plaque formation. Experts reviewed the latest findings at this year’s Annual Meeting of the Austrian Alzheimer Society in Vienna.

In 1906, the physician Alois Alzheimer first described the neuropathological features of “progressive dementia”, which have today been identified as beta-amyloid plaques and neurofibrillary tangles. The way in which these deposits are created, and the pathological processes which they trigger in the brain, are relatively well-researched. The biomolecular findings from this research have offered a wide range of targets for new medications, and some of these have delivered promising preclinical results which are now being tested in phase II and III studies.

Secretase modulators and beta-sheet breakers Prof. Dr. Reinhold Schmidt, from the Medical University of Graz, addressed the topics of secretase inhibitors, metal chelators and immunological approaches. The goal is hereby to prevent or reduce the amyloid deposits which increasingly appear in the brains of Alzheimer’s patients. Amyloid deposits result from protein fragments which are separated from the amyloid precursor protein (PPP) by beta and gamma secretases and which clump together into insoluble aggregates. The inhibition of gamma secretase is of greatest pharmacological interest here. However, the problem is that the highly complex enzyme does not only split APPs, but is probably also involved in life-sustaining processes such as haematopoiesis. “For this reason, increasing emphasis is being placed on secretase modulators,” explained Schmidt. “The secretases still split amyloid fragments from the precursor protein. However, this produces more soluble fragments with 38 to 40 amino acids instead of insoluble fragments with 42 amino acids (A. 42).”